StockNews.AI
NBIX
StockNews.AI
13 days

Neurocrine Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference

1. Neurocrine Biosciences will present at Canaccord Genuity Growth Conference. 2. CEO Kyle Gano and VP Todd Tushla will speak at the event. 3. Live webcast and replay available on Neurocrine's website. 4. Company focuses on neuroscience with multiple FDA-approved treatments. 5. Robust pipeline includes drugs in mid- to late-phase development.

4m saved
Insight
Article

FAQ

Why Bullish?

Participation in prominent conferences often boosts investor confidence and visibility. Historical data shows that such presentations frequently lead to positive stock movements.

How important is it?

The conference provides a platform to showcase Neurocrine's efforts and pipeline, impacting investor sentiment positively.

Why Short Term?

The upcoming conference will provide immediate insights and potential updates on pipeline drugs.

Related Companies

ABBVBIIBVRTX
, /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Canaccord Genuity 45th Annual Growth Conference at 8:00 a.m. ET on Wednesday, August 13, 2025. Chief Executive Officer Kyle Gano and Vice-President of Investor Relations Todd Tushla will present at the conference. The live webcast can be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month. About Neurocrine BiosciencesNeurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X and Facebook.(*in collaboration with AbbVie) NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc. SOURCE Neurocrine Biosciences, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News